Skip to main content

VitaNova Life Sciences Corp

corporate_fare Company Profile

VitaNova Life Sciences Corp

VNOV·OTC·Trade & Services·CIK 0001699709

Yijia Group Corp. was incorporated on January 25, 2017, and commenced operations on July 30, 2021. The company provides business consulting services to domestic and international customers, focusing on funding and other financial matters. On November 9, 2023, Yijia Group Corp. founded Nutripeak Trading Corporation, a wholly owned Nevada subsidiary, to market and supply healthcare products. The company operates in two main segments. The Consulting Service Segment offers advisory services in management business, accounting, and finance. The Healthcare Segment provides healthcare products and health consultation services. Yijia Group Corp.'s core products are anti-aging products designed to increase NAD+ levels, which are promoted for anti-aging, enhanced energy metabolism, improved cognitive function, and strengthened cellular repair capabilities. In addition to these products, the company offers professional health consultation services, where health advisors provide personalized advice, recommend supplements, and design customized nutrition and wellness plans based on individual customer needs, physical conditions, health goals, and lifestyle habits. The company utilizes a multi-channel sales and marketing approach for its anti-aging products, including e-commerce platforms, its own website, brick-and-mortar stores, social media, and direct sales. To address market competition, Yijia Group Corp. emphasizes continuous product innovation and development, brand strengthening through advertising, participation in trade shows, and sponsoring public welfare projects.

VitaNova Life Sciences Corp (OTC:VNOV) is a publicly traded company in the Trade & Services sector. Wiseek monitors VNOV SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • VitaNova Reports Q3 Loss, Strong Revenue Growth, and Material Weaknesses in Internal Controls

Financial Snapshot

Fiscal year ended April 30, 2025
Revenue
$2.66M
Net Income
$850.75K
Diluted EPS
$0.03
Op. Cash Flow
$192.77K
Gross Profit
$1.58M
Operating Income
$1.21M
Cash & Equivalents
$782.81K
Debt / Equity
0.00×
Net Margin
32.0%
Shares Outstanding
25.01M sh
Source: 10-K · filed 2025-07-24 · accession 0001683168-25-005368
Browse all tickers starting with V →
$1.38
52-week range · as of 2026-03-16 $1.27 – $45
Market cap
$11.51M
Volume
2.4K (11.3× avg)
3-mo avg 217
Live data · 2026-06-14 03:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VNOV - Latest Insights

VNOV
Mar 16, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.83
Real-time Price: $1.38 info
Change: -$3.45 (-71%) info
Market Cap: $11.506M info